Previous Close | 3.4600 |
Open | 3.4500 |
Bid | 3.3900 x 1100 |
Ask | 3.5000 x 1200 |
Day's Range | 3.2600 - 3.4700 |
52 Week Range | 0.5300 - 3.8500 |
Volume | |
Avg. Volume | 1,360,014 |
Market Cap | 244.306M |
Beta (5Y Monthly) | 0.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1200 |
Earnings Date | Mar 29, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.21 |
Subscribe to Yahoo Finance Plus to view Fair Value for PRQR
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with the European Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company’s proprietary Axiomer® RNA editing technology platform at upcoming scientific and industry conferences, including the 8th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA Leaders
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team. During the event, the Company will showcase its proprietary Axiomer® RNA-editing technology platform